Last checked at 
LONDON (Alliance News) - Neuroscience company Cambridge Cognition Holdings PLC on Wednesday said it has signed a GBP500,000 deal for its CANTAB Connect Research product.
The deal has been inked with an unnamed biobank, which amasses data and biological samples and catalogues them based on genetic, biological, environmental and other traits.
The contract will allow for cognitive assessments using the CANTAB products to be conducted, generating results for use in medical research into assessing mental health.
"Biobanks play a crucial role in biomedical research, enabling pharmaceutical companies to translate research into better treatments. We are therefore excited to be working in partnership with biobanks internationally, helping them advance drug development by enhancing their research capabilities," said Cambridge Cognition Chief Executive Steven Powell.
Cambridge Cognition shares were up 4.0% to 33.80 pence Wednesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
